GlassScriptPhysician profile
Ashish Asawa
NPI 1073712360
$5,010.21
in general payments reported to CMS, 2019-2025
27 companies · $2,098 in 2025
The $2,098 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $100 · 2021: $68.14 · 2022: $446 · 2023: $993 · 2024: $991 · 2025: $2,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,985 · Education: $97.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,984.99 |
| Education | $97.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,256.72 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $824.06 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $462.78 | 2019-2025 | |
| Genzyme Corporation | $373.04 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $324.83 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Regeneron Healthcare Solutions, INC. | $324.04 | 2022-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $193.47 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $188.87 | 2019-2025 | |
| Kaleo, INC. | $174.06 | 2022-2023 | Auvi-Q |
| Pfizer INC. | $126.21 | 2023-2025 | |
| Galderma Laboratories, L.P. | $115.94 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $102.80 | 2019 | |
| Abbvie INC. | $99.06 | 2024 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2025 | |
| Incyte Corporation | $52.70 | 2024 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $48.26 | 2024 | Nuvent, Sinuva |
| Csl Behring | $43.65 | 2023-2024 | Hizentra, Haegarda |
| Gc Biopharma USA, INC. | $31.66 | 2025 | Alyglo |
| Stryker Corporation | $28.85 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $28.51 | 2025 | Dupixent |
| Amgen INC. | $23.37 | 2023 | Tezspire |
| Azurity Pharmaceuticals, INC. | $21.43 | 2025 | Alvesco |
| Greer Laboratories, INC. | $21.16 | 2022 | |
| Acclarent, INC | $19.95 | 2021 | |
| Biocryst US Sales Co., LLC | $17.05 | 2023 | Orladeyo |
| Olympus America INC. | $15.38 | 2023 | Olympus |
| Inspire Medical Systems, INC. | $15.37 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Asawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.